✦ LIBER ✦

3. Clinical outcome following 8-year enzyme replacement therapy in 884 children with type 1 Gaucher disease (GD1)

✍ Scribed by Hans Andersson; Paige Kaplan; Kathrine Kacena; John Yee

Book ID: 116988188
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 74 KB
Volume: 93
Category: Article
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2007.10.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Eight-Year Clinical Outcomes of Long-Ter

Eight-Year Clinical Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children With Gaucher Disease Type 1

✍ Andersson, Hans (author);Kaplan, Paige (author);Kacena, Katherine (author);Yee, 📂 Article 📅 2008 🏛 American Academy of Pediatrics 🌐 English ⚖ 631 KB

Eight-Year Clinical Outcomes of Long-Ter

Eight-Year Clinical Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children With Gaucher Disease Type 1

✍ Andersson, Hans (author);Kaplan, Paige (author);Kacena, Katherine (author);Yee, 📂 Article 📅 2008 🏛 American Academy of Pediatrics 🌐 English ⚖ 631 KB

Clinical Consequences of Interrupting En

Clinical Consequences of Interrupting Enzyme Replacement Therapy in Children with Type 1 Gaucher Disease

✍ Guillermo Drelichman; Elvira Ponce; Nora Basack; Daniel Freigeiro; Luis Aversa; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 361 KB

Acute lymphoblastic leukemia in a patien

Acute lymphoblastic leukemia in a patient with type 1 Gaucher disease developing 1 year after discontinuation of enzyme replacement therapy

✍ Aditi Ranade; Sorin Selegean; Gagangeet Sandhu; Violette Ghali; Vijay P. Shah 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 1 views

Higher rates of venous thromboembolism for Black-Americans are likely due to lower serum ## 25-hydroxyvitamin D levels To the editor: The recent paper on disparities of thromboembolism in the United States concluded that heritability may be important in the etiology of venous thromboembolism amon

156. Enzyme replacement therapy with vel

156. Enzyme replacement therapy with velaglucerase alfa improves key clinical parameters in a pediatric subgroup with type 1 Gaucher disease

✍ Ari Zimran; Derlis Gonzalez; Eric Crombez; Kiran Bhirangi 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Achievement of Therapeutic Goals Over 2

Achievement of Therapeutic Goals Over 2 Years of Velaglucerase Alfa Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease

✍ Deborah Elstein; Hadhami Ben Turkia; Madhulika Kabra; Pilar Giraldo; Marie-Franç 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB